Menasche P, Dunica S, Kural S, Touchot B, Chollet A, Steg G, Levard G, Lorente P, Piwnica A
J Thorac Cardiovasc Surg. 1984 Aug;88(2):278-86.
The protection afforded by cardioplegia during elective ischemic arrest can be partly compromised by a reperfusion injury, which may impede the recovery of cardiac function. We previously showed experimentally that this postischemic damage could be largely avoided by an appropriate crystalloid reperfusate. The present study was thus undertaken to assess the effects of this "reperfusion solution" clinically. One hundred twelve patients undergoing valve replacement with the aid of hypothermic cardioplegia (K+ 12 mEq, Mg2+ 26 mEq) were prospectively divided in two groups: Group I (n = 49) received an unmodified blood reperfusate. In Group II (n = 63), 1 L of the reperfusion solution was delivered just prior to removal of the aortic clamp. The formulation of the reperfusion solution adhered to the following principles: (1) maintenance of cardioplegia (K+ = 15 mEq), (2) replenishment of Ca2+ stores (Ca2+ = 2.5 mEq), (3) substrate provision (glutamate = 2,942 gm), (4) buffering (pH = 7.70 at 28 degrees C), and (5) hyperosmolarity (370 mOsm). The two groups were matched for preoperative data except for a higher incidence of isolated aortic valve replacement (p = 0.01) in Group II. Also, the cross-clamp time (mean +/- standard error of the mean) was longer in Group II (94 +/- 4 minutes versus 63 +/- 4 minutes, p less than 10(-6]. The reperfusion solution was found to increase both the rate and extent of postischemic functional recovery, as evidenced by (1) a lower proportion of catecholamine-supported patients 48 hours after operation (9/63 [14.28%] versus 16/49 [32.6%] in the control group [p less than 0.03]) and (2) a lower amount (gamma/kg/min) of dobutamine required to achieve stable hemodynamics (11 +/- 1 versus 26 +/- 6 in the control group [p less than 0.03]). A similar recovery pattern was noted in the high-risk subgroup of patients with mitral valve disease. Further, serial postoperative hemodynamic measurements were performed in 31 randomly selected patients (10 control and 21 reperfused). Although the reperfused patients were found to be at higher risk because of lower preoperative cardiac indices and longer cross-clamp times, they consistently achieved better postoperative hemodynamics with a lower incidence of catecholamine support. This hemodynamic improvement was particularly reflected by a higher left ventricular stroke work index throughout the postoperative course, the difference being significant 6 hours and 12 hours postoperatively.(ABSTRACT TRUNCATED AT 400 WORDS)
在择期缺血性心脏停搏期间,心脏停搏液提供的保护作用可能会因再灌注损伤而部分受损,这可能会阻碍心功能的恢复。我们之前通过实验表明,通过合适的晶体再灌注液可在很大程度上避免这种缺血后损伤。因此,本研究旨在临床评估这种“再灌注溶液”的效果。112例在低温心脏停搏液(钾离子12毫当量,镁离子26毫当量)辅助下进行瓣膜置换的患者被前瞻性地分为两组:第一组(n = 49)接受未改良的血液再灌注液。第二组(n = 63)在移除主动脉夹之前即刻输注1升再灌注溶液。再灌注溶液的配方遵循以下原则:(1)维持心脏停搏液(钾离子 = 15毫当量),(2)补充钙离子储备(钙离子 = 2.5毫当量),(3)提供底物(谷氨酸 = 2942克),(4)缓冲(28摄氏度时pH = 7.70),以及(5)高渗(370毫渗量)。除了第二组孤立主动脉瓣置换的发生率较高(p = 0.01)外,两组术前数据匹配。此外,第二组的主动脉阻断时间(平均值±平均标准误)更长(94±4分钟对63±4分钟,p<10⁻⁶)。发现再灌注溶液可增加缺血后功能恢复的速率和程度,证据如下:(1)术后48小时依赖儿茶酚胺支持的患者比例较低(63例中有9例[14.28%],对照组49例中有16例[32.6%][p<0.03]),以及(2)达到稳定血流动力学所需的多巴酚丁胺量(微克/千克/分钟)较低(对照组为26±6,第二组为11±1[p<0.03])。在二尖瓣疾病的高危亚组患者中也观察到类似的恢复模式。此外,对31例随机选择的患者(10例对照组和21例再灌注组)进行了术后系列血流动力学测量。尽管由于术前心脏指数较低和主动脉阻断时间较长,再灌注组患者被发现风险更高,但他们术后血流动力学始终更好,儿茶酚胺支持的发生率更低。这种血流动力学改善在术后整个过程中尤其体现在左心室每搏功指数更高,术后6小时和12小时差异显著。(摘要截短至400字)